Literature DB >> 25693592

Sonic Hedgehog pathway is upregulated in adamantinomatous craniopharyngiomas.

D C Gomes1, S A Jamra2, L F Leal2, L M Colli2, M L Campanini2, R S Oliveira2, C E Martinelli2, P C L Elias2, A C Moreira2, H R Machado2, F Saggioro2, L Neder2, M Castro2, S R Antonini3.   

Abstract

OBJECTIVES: Pituitary stem cells play a role in the oncogenesis of human adamantinomatous craniopharyngiomas (aCPs). We hypothesized that crosstalk between the Wnt/β-catenin and Sonic Hedgehog (SHH) pathways, both of which are important in normal pituitary development, would contribute to the pathogenesis of aCPs.
DESIGN: To explore the mRNA and protein expression of components of the SHH signaling pathway in aCPs and their relationship with the identification of CTNNB1/β-catenin mutations and patients outcomes. PATIENTS AND METHODS: In 18 aCP samples, CTNNB1 was sequenced, and the mRNA expression levels of SHH pathway members (SHH, PTCH1, SMO, GLI1, GLI2, GLI3, and SUFU) and SMO, GLI1, GLI3, SUFU, β-catenin, and Ki67 proteins were evaluated by quantitative real-time PCR and immunohistochemistry respectively. Anterior normal pituitaries were used as controls. Associations between molecular findings and clinical data were analyzed.
RESULTS: The aCPs presented higher mRNA expression of SHH (+400-fold change (FC); P<0.01), GLI1 (+102-FC; P<0.001), and GLI3 (+5.1-FC; P<0.01) than normal anterior pituitaries. Longer disease-free survival was associated with low SMO and SUFU mRNA expression (P<0.01 and P=0.02 respectively). CTNNB1/β-catenin mutations were found in 47% of the samples. aCPs with identified mutations presented with higher mRNA expression of SMO and GLI1 (+4.3-FC; P=0.02 and +10.2-FC; P=0.03 respectively). SMO, GLI1, GLI3, and SUFU staining was found in 85, 67, 93, and 64% of the samples respectively. Strong GLI1 and GLI3 staining was detected in palisade cells, which also labeled Ki67, a marker of cell proliferation.
CONCLUSIONS: The upregulation of SHH signaling occurs in aCPs. Thus, activation of Wnt/β-catenin and SHH pathways, both of which are important in pituitary embryogenesis, appears to contribute to the pathogenesis of aCP.
© 2015 European Society of Endocrinology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25693592     DOI: 10.1530/EJE-14-0934

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  14 in total

Review 1.  Can tissue biomarkers reliably predict the biological behavior of craniopharyngiomas? A comprehensive overview.

Authors:  Ruth Prieto; José M Pascual
Journal:  Pituitary       Date:  2018-08       Impact factor: 4.107

2.  Pediatric craniopharyngioma in association with familial adenomatous polyposis.

Authors:  Nathan A Dahl; Drew Pratt; Sandra Camelo-Piragua; Chandan Kumar-Sinha; Rajen J Mody; Seth Septer; Todd C Hankinson; Arul M Chinnaiyan; Carl Koschmann; Lindsey Hoffman
Journal:  Fam Cancer       Date:  2019-07       Impact factor: 2.375

3.  Molecular defects in BRAF wild-type ameloblastomas and craniopharyngiomas-differences in mutation profiles in epithelial-derived oropharyngeal neoplasms.

Authors:  Stephan Bartels; Akinyele Adisa; Timothy Aladelusi; Juliana Lemound; Angelika Stucki-Koch; Sami Hussein; Hans Kreipe; Christian Hartmann; Ulrich Lehmann; Kais Hussein
Journal:  Virchows Arch       Date:  2018-03-15       Impact factor: 4.064

4.  Distinct patterns of primary and motile cilia in Rathke's cleft cysts and craniopharyngioma subtypes.

Authors:  Shannon Coy; Ziming Du; Shu-Hsien Sheu; Terri Woo; Fausto J Rodriguez; Mark W Kieran; Sandro Santagata
Journal:  Mod Pathol       Date:  2016-08-26       Impact factor: 7.842

5.  Identification of targets for rational pharmacological therapy in childhood craniopharyngioma.

Authors:  Jacob M Gump; Andrew M Donson; Diane K Birks; Vladimir M Amani; Karun K Rao; Andrea M Griesinger; B K Kleinschmidt-DeMasters; James M Johnston; Richard C E Anderson; Amy Rosenfeld; Michael Handler; Lia Gore; Nicholas Foreman; Todd C Hankinson
Journal:  Acta Neuropathol Commun       Date:  2015-05-21       Impact factor: 7.801

6.  The Stem Cell Connection of Pituitary Tumors.

Authors:  Hugo Vankelecom; Heleen Roose
Journal:  Front Endocrinol (Lausanne)       Date:  2017-12-04       Impact factor: 5.555

Review 7.  Genetically engineered mouse models of craniopharyngioma: an opportunity for therapy development and understanding of tumor biology.

Authors:  John Richard Apps; Juan Pedro Martinez-Barbera
Journal:  Brain Pathol       Date:  2017-05       Impact factor: 6.508

8.  Ki67 as a prognostic factor of craniopharyngioma's recurrence in paediatric population.

Authors:  Elżbieta Moszczyńska; Monika Prokop-Piotrkowska; Agnieszka Bogusz-Wójcik; Wiesława Grajkowska; Sylwia Szymańska; Mieczysław Szalecki
Journal:  Childs Nerv Syst       Date:  2020-02-07       Impact factor: 1.475

9.  Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK/ERK pathway as a novel therapeutic target.

Authors:  John R Apps; Gabriela Carreno; Jose Mario Gonzalez-Meljem; Scott Haston; Romain Guiho; Julie E Cooper; Saba Manshaei; Nital Jani; Annett Hölsken; Benedetta Pettorini; Robert J Beynon; Deborah M Simpson; Helen C Fraser; Ying Hong; Shirleen Hallang; Thomas J Stone; Alex Virasami; Andrew M Donson; David Jones; Kristian Aquilina; Helen Spoudeas; Abhijit R Joshi; Richard Grundy; Lisa C D Storer; Márta Korbonits; David A Hilton; Kyoko Tossell; Selvam Thavaraj; Mark A Ungless; Jesus Gil; Rolf Buslei; Todd Hankinson; Darren Hargrave; Colin Goding; Cynthia L Andoniadou; Paul Brogan; Thomas S Jacques; Hywel J Williams; Juan Pedro Martinez-Barbera
Journal:  Acta Neuropathol       Date:  2018-03-14       Impact factor: 17.088

10.  The landscape of genetic alterations in ameloblastomas relates to clinical features.

Authors:  Sibel Elif Gültekin; Reem Aziz; Carina Heydt; Burcu Sengüven; Joachim Zöller; Ali Farid Safi; Matthias Kreppel; Reinhard Buettner
Journal:  Virchows Arch       Date:  2018-02-01       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.